CAMBRIDGE, Mass. (AP) _ Blueprint Medicines Corp. (BPMC) on Wednesday reported a loss of $318.7 million in its fourth quarter.On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $5.40. Losses, adjusted for research and development costs, came to 99 cents per share.The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 71 cents per share.The cancer drug developer posted revenue of $107 million in the period, which topped Street forecasts. Eight analysts surveyed by Zacks expected $103.7 million.For the year, the company reported a loss of $644.1 million, or $11.01 per share, swinging to a loss in the period. Revenue was reported as $180.1 million.Blueprint Medicines shares have fallen 30% since the beginning of the year. The stock has declined 25% in the last 12 months.ADVERTISEMENT_____This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BPMC at https://www.zacks.com/ap/BPMC